1) Sitteen patients of anemia of old age, who had been orally given iron in therapy for iron-deficiency anemia but made little progress towards recovery, were subjected to an additional administration of a combination of 60-120mg of ATP and 1, 000mg of vitamin C. As a result, fourteen patients showed a rise of serum iron level accompanied by increases in hemoglobin value and red cell count. 2) Normal rabbits were intramuscularly injected with 100mg of ATP in combination with 50mg of vitamin C. Then, by using Fe59, relative radioactivities of such organs as liver, spleen, bone marrow and kidney were measured, and an outstanding radioactivity was observed in liver. In addition, the measurement of organic iron in individual organs indicated an increase in organic iron in liver and spleen, and rom the histological viewpoint the precipitation of hemosiderin was noticed in liver and spleen. At the same time, a decrease in serum iron was also noticed. The above findings have led the writers to the assumption that the administration of ATP and vitamin C promoted the iron metabolism.
Authors have found that the content of nucleic acids and protein in human peripheral blood lymphocytes correlate well with the subjects age. Forty-two persons (20 males, 22 females, aged 4-77) were utilized as a control. 8 persons with acute inflammatory diseases and a case of Werner's syndrome were also analized. Lymphocytes were incubated with 14C-leucine and 2P-orthophosphate and then nucleic acids and protein were estimated both colorimetrically and radiologically. Mean lymphocyte DNA content was 7.00±0.19μg. per million cells, and this value was extremely constant for all subjects. Thus the ratio of RNA/DNA and the ratio of protein/DNA was taken as a reliable index of changes in RNA and protein content of the lymphocytes. The ratio of RNA/DNA and the ratio of protein/DNA declined until the mid-twenties, and then rose steadily with age. A 44-year old pateints with Werner's syndrome had these ratios of a control nearly 65 years old, an age which entailed with his appearance and with results of clinical examinations. In patients with acute inflammatory diseases, however, these ratios were much higher than the values expected from their chronological ages. We could differentiate patients with these diseases from the controls and from the patient with Werner's syndrome with the aid of the estimation of radioactivity in the protein which decreased steadily with age in controls and was much higher in patients with acute inflammatory diseases. These observations in human lymphocytes were well correspondent in the case of nuclear fraction of rat kidney.
This report is the result of pyridinolcarbamate treatment of atherosclerosis of cholesterol-fed rabbits. 124 healthy albino male rabbits which had bred in our own farm and had the same age of 6 months, were kept on pellets contaning 1% cholesterol for 15 weeks for the production of atherosclerotic rabbits. At the end of this period, cholesterol pellets were taken off and they were returned to a normal diet. These 124 atheromatous rabbits were divided into two groups (Placebo control group and pyridinolcarbamate group). The placebo control group received gelatin capsule containing potato starch as a placebo, and the treated group recieved gelatin capsule containing pyridinolcarbamate in a daily dose of 10-20-30mg/kg by mouth. Each same number of animals (5 or 7) of both groups were sacrificed on the 4th, 7th day, 3rd, 6th, 10th, 20th and 30th week of the treatment under normal diet. The aorta was examined histologically and biochemically under the double blind technique. Results: During this experiment, there was no statistically significant difference between the placebo control and pyridinolcarbamate group in daily food consumption, body weight and serum total cholesterol level. Histological observations: In the placebo control group, an abundant accumulation of fatty substances and a scantiness of regressive changes were characteristic and these features still remained even 10-20 weeks after the withdrawal of cholesterol. Thirty weeks after the withdrawal of cholesterol, fibrous caps were produced covering atheromatous masses, but there are abundant sudanophilic substances in the central portion of the atheromatous lesions covered by the fibrous cap. In treated group, the rapid disappearance of edema and the appearance of smooth muscle fibers inside the atheromatous lesion was characteristic in the short term of pyridinolcarbamate treatment and after the 10 weeks of pyridin olcarbamate treatment atheromatous lesions were almost completely replaced with the regenerated smooth muscle fibers. Biochemical measurement of cholesterol content of arterial walls: In rabbits treated by pyridinolcarbamate more than 6 weeks the cholesterol content of aortic wall was significantly lowered in the pyridinolcarbamate group than placebo control group (P<0.05). There was found no apparent toxic effect in the biological and histological analysis in animals received pyridinolcarbamate. The administration of pyridinolcarbamate in a daily dose of 10 to 30mg has been shown to promote significantly the naturally occuring healing in atheromatous lesions of cholesterol-fed rabbits and the replacement of atheromatous masses with regenerated smooth muscle fibres has been noted as a highly important finding in pyridinolcarbamate treatment of atheromatous lesions.